Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1977 Dec;53(626):745–748. doi: 10.1136/pgmj.53.626.745

Recovery of hypothalamic-pituitary-adrenal function after intermittent high-dose prednisolone and cytotoxic chemotherapy.

K S Wilson, C E Gray, G P Lidgard, A C Parker
PMCID: PMC2496786  PMID: 604989

Abstract

Hypothalamic/pituitary and adrenal (HPA) function was assessed in ten patients who received intermittent high-dose prednisolone and cytotoxic chemotherapy for 5-40 months. Standard insulin hypoglycaemia (IHT), thyrotrophin-releasing hormone and tetracosactrin tests were performed 36 hr after the last dose of prednisolone and subsequently 10 days--52 weeks after completion of all chemotherapy. In the first tests there was evidence of impaired hypothalamic-pituitary function judged by peak adrenocorticotrophic hormone (ACTH), growth hormone (GH) and thyrotrophin (TSH) responses, and corresponding plasma corticosteroid responses were sub-normal in five patients. In the final IHTs, seven patients had persistently subnormal ACTH responses but all the corresponding plasma corticosteroid responses returned to normal. Mean peak corticosteroid responses to insulin and tetracosactrin and peak GH responses were significantly greater than in the first tests. Such chemotherapy regimens may have prolonged effects on hypothalamic/pituitary function but the demonstration of normal corticosteroid responses to hypoglycaemia and tetracosactrin indicates that these patients' stress responses will be normal as early as 10 days after treatment is stopped.

Full text

PDF
745

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R., Haut A., Khan A. U., Lane M., McKelvey E. M., Migliore P. J., Stuckey W. J., Jr, Wilson H. E. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969 Jun 2;208(9):1680–1685. doi: 10.1001/jama.208.9.1680. [DOI] [PubMed] [Google Scholar]
  2. Angeli A., Frajria R., Boccuzzi G., Bisbocci D., Ceresa F. Paradoxical response of plasma cortisol to pulse intravenous injection of synthetic corticotrophin and dibutyryl cyclic adenosine 3',5'-monophosphate in adult panhypopituitarism. Acta Endocrinol (Copenh) 1973 Oct;74(2):250–262. doi: 10.1530/acta.0.0740250. [DOI] [PubMed] [Google Scholar]
  3. Daly J. R., Fletcher M. R., Glass D., Chambers D. J., Bitensky L., Chayen J. Comparison of effects of long-term corticotrophin and corticosteroid treatment on responses of plasma growth hormone, ACTH, and corticosteroid to hypoglycaemia. Br Med J. 1974 Jun 8;2(5918):521–524. doi: 10.1136/bmj.2.5918.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Devita V. T., Jr, Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970 Dec;73(6):881–895. doi: 10.7326/0003-4819-73-6-881. [DOI] [PubMed] [Google Scholar]
  5. HARTOG M., GAAFAR M. A., FRASER R. EFFECT OF CORTICOSTEROIDS ON SERUM GROWTH HORMONE. Lancet. 1964 Aug 22;2(7356):376–378. doi: 10.1016/s0140-6736(64)90389-7. [DOI] [PubMed] [Google Scholar]
  6. Hall R., Ormston B. J., Besser G. M., Cryer R. J. The thyrotrophin-releasing hormone test in diseases of the pituitary and hypothalamus. Lancet. 1972 Apr 8;1(7754):759–763. doi: 10.1016/s0140-6736(72)90518-1. [DOI] [PubMed] [Google Scholar]
  7. LANDON J., WYNN V., JAMES V. H. THE ADRENOCORTICAL RESPONSE TO INSULIN-INDUCED HYPOGLYCAEMIA. J Endocrinol. 1963 Nov;27:183–192. doi: 10.1677/joe.0.0270183. [DOI] [PubMed] [Google Scholar]
  8. Malone D. N., Grant I. W., Percy-Robb I. W. Hypothalamo-pituitary-adrenal function in asthmatic patients receiving long-term corticosteroid therapy. Lancet. 1970 Oct 10;2(7676):733–735. doi: 10.1016/s0140-6736(70)90217-5. [DOI] [PubMed] [Google Scholar]
  9. Naysmith A., Hancock B. W., Cullen D. R., Richmond J., Wilde C. E. Pituitary function in patients receiving intermittent cytotoxic and corticosteroid therapy for malignant lymphoma. Lancet. 1976 Apr 3;1(7962):715–717. doi: 10.1016/s0140-6736(76)93090-7. [DOI] [PubMed] [Google Scholar]
  10. Otsuki M., Dakoda M., Baba S. Influence of glucocorticoids on TRF-induced TSH response in man. J Clin Endocrinol Metab. 1973 Jan;36(1):95–102. doi: 10.1210/jcem-36-1-95. [DOI] [PubMed] [Google Scholar]
  11. Staub J. J., Jenkins J. S., Ratcliffe J. G., Landon J. Comparison of corticotrophin and corticosteroid response to lysine vasopressin, insulin, and pyrogen in man. Br Med J. 1973 Feb 3;1(5848):267–269. doi: 10.1136/bmj.1.5848.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Toft A. D., Seth J., Kirkham K. E., Marshall A., Irvine W. J. Assessment of in vitro thyroid function tests in 100 consecutive patients referred to a thyroid clinic. Clin Endocrinol (Oxf) 1973 Apr;2(2):127–134. doi: 10.1111/j.1365-2265.1973.tb00412.x. [DOI] [PubMed] [Google Scholar]
  13. Wilson K. S., Gray C. E., Cameron E. H., Seth J., Parker A. C. Hypothalamic/pituitary/adrenal function in patients treated with intermittent high-dose prednisolone and cytotoxic chemotherapy. Lancet. 1976 Mar 20;1(7960):610–612. doi: 10.1016/s0140-6736(76)90417-7. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES